Chk1 Inhibition Ameliorates Alzheimer’s Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling. The gene discussed is PTPA; the disease is early-onset autosomal dominant Alzheimer disease.